Neutrophil reduction after chemotherapy
Conditions
Interventions
Case series:48h after chemotherapy, JinyouLi 3mg/times, 1 injection per chemotherapy cycle.
Sponsors
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged at least 18 years male or female; 2. Patients diagnosed with solid tumors by histopathology or cytology; 3. Patients requiring multiple cycles of chemotherapy alone; 4. 10% 2.0); (6) Renal dysfunction (Ccr 65 years receiving adequate dose-intensive chemotherapy; 5. KPS=70; 6. Life expectancy is more than 3 months; 7. Hematopoietic function: ANC =1.5×10^9/L; PLT=80×10^9/L; Hb= 75g/LWBC =3.0×10^9/L; 8. All patients must agree to take effective contraception during the study period and within 6 months of cessation of treatment, and women of childbearing age must have a negative urine pregnancy test before treatment; 9. All the subjects (or their legal representatives/guardians) were required to provide written informed consent prior to enrollment.
Exclusion criteria
Exclusion criteria: 1. Hematopoietic stem cell or organ transplant recipients; 2. Uncontrolled local or systemic infection; 3. Severe dysfunction of internal organs and myocardial infarction occurred in the past 6 months; 4. Liver function: TBIL, ALT and AST are all > 2.5 times the upper limit of normal, if the liver metastasis is due to the above indicators>5 times the upper limit of normal; renal function: Cr> 2 times the upper limit of normal; 5. Hypersplenism; 6. Use other drugs of the same type or clinical trials of other drugs within 4 weeks before enrollment; 7. Allergy to PEG-rhG-CSF, rhG-CSF, and other agents or proteins expressed in Escherichia coli; 8. Severe mental illness, affecting informed consent and/or describing or observing adverse reactions; 9. Pregnancy or breastfeeding women, women of childbearing age refused to accept contraceptives; 10. Patients who are not suitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of III/IV ANC reduction in each chemotherapy cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and duration of FN in each chemotherapy cycle;Chemotherapy dosage adjustment or delayed chemotherapy for each chemotherapy cycle;Proportion of patients receiving antibiotic treatment during chemotherapy; | — |
Countries
China
Contacts
Public ContactHu Guangyuan
Tongji Hospital of Tongji Medical College, Huazhong
Outcome results
None listed